Cover Image
市場調查報告書

治療疫苗的全球市場:成長率、市場趨勢、市場預測

Global Therapeutic Vaccines Market - Growth, Trends & Forecasts (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 391468
出版日期 內容資訊 英文 211 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
治療疫苗的全球市場:成長率、市場趨勢、市場預測 Global Therapeutic Vaccines Market - Growth, Trends & Forecasts (2017 - 2022)
出版日期: 2016年12月15日 內容資訊: 英文 211 Pages
簡介

本報告提供全球治療疫苗的市場調查,市場定義和概要,市場的影響因素及市場機會分析,各疫苗區分、詳細產品、地區、主要國家趨勢,競爭環境與主要企業簡介,未來展望等彙整資料。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 主要推論

第5章 市場概要、產業趨勢

  • 目前市場方案
  • 波特的五力分析

第6章 市場促進因素、阻礙要素、市場機會、課題

  • 成長推動因素
  • 阻礙成長要素
  • 市場機會
  • 市場課題

第7章 市場區隔

  • 各類型
    • 自體免疫疾病疫苗
    • 神經疾病疫苗
    • 癌症疫苗
    • 感染疾病疫苗
  • 各地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 法國
      • 英國
      • 義大利
      • 西班牙
      • 斯堪地那維亞各國
      • 荷比盧三國
      • 其他
    • 亞太地區
      • 日本
      • 中國
      • 印度
      • 韓國
      • 澳洲&紐西蘭
      • 其他
    • 中東、非洲
      • GCC各國
      • 南非
      • 其他
    • 南美
      • 巴西
      • 阿根廷
      • 其他

第8章 競爭環境

  • M&A分析
  • 合作、聯盟
  • 新產品的投入

第9章 主要供應商分析

  • Agenus Inc
  • Bavarian Nordic
  • Celtic Pharma
  • Cytos Biotechnology
  • Dendreon Corp
  • GlaxoSmithKline
  • Pfizer
  • Merck Serono
  • Novartis
  • Transgene

第10章 未來展望

目錄

The global therapeutic vaccines market valued at USD 11 billion in 2016 and is projected to reach USD 51 billion by 2022, at a CAGR of 29% during the forecast period. The increasing prevalence of chronic diseases, such as cancer and HIV/AIDS are fuelling the market growth.

Market Dynamics

The favorable funding for R&D, increasing investments by companies, and rise in the prevalence of chronic diseases are some of the factors that are propelling the growth of the market. However, high costs of the vaccines and stringent regulatory guidelines are turning out to be restraints for this market.

Market Segmentation

The global therapeutic vaccines market has been segmented by type and geography.

Type -

  • Auto Immune Diseases Vaccines
  • Neurological Disease Vaccines
  • Cancer Vaccines
  • Infectious Diseases Vaccines

The cancer vaccines sub-segment contributes the highest share.

Geography -

  • North America
  • Europe
  • Asia-Pacific
  • The Middle East and Africa
  • South America

North America has the largest market size, followed by Europe. Asia-Pacific is an emerging market for vaccines, owing to the rising population and large investments in the field of research and development.

Numerous players in this market are trying to expand their product portfolio in order to top the global market. Few companies have adopted product innovation and new product launches as their key business strategies to ensure their dominance in the market.

The major players in the therapeutic vaccines market are:

  • Agenus Inc.
  • Bavarian Nordic
  • Celtic Pharma
  • Cytos Biotechnology
  • Dendreon Corp
  • GlaxoSmithKline Plc
  • Pfizer Inc
  • Merck Serono
  • Novartis
  • Transgene S.A
  • Sanofi Pasteur
  • Others

Key Deliverables In The Study

  • Market analysis for the global therapeutic vaccines market, with region specific assessments and competition analysis.
  • Market definition along with the identification of key drivers, restraints, opportunities and challenges.
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
  • Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.
  • Identification and analysis of the macro and micro factors that affect the global therapeutic vaccines market.
  • Insights of the market in the regions that have the highest potential for growth and also to identify the markets that are still untapped

Table of Contents

1. Introduction

  • 1.1. Study Deliverables
  • 1.2. Market Definition
  • 1.3. General Study Assumptions
  • 1.4. Report Description

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Analysis Methodology
  • 2.3. Study timeline
  • 2.4. Study Phases
    • 2.4.1. Secondary Research
    • 2.4.2. Discussion Guide
    • 2.4.3. Market Engineering & Econometric Model
    • 2.4.4. Expert Validation

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry trends

  • 5.1. Current Market Scenario
  • 5.2. Porter's Five Force Analysis
    • 5.2.1. Bargaining Power of Suppliers
    • 5.2.2. Bargaining Power of Consumers
    • 5.2.3. Threat to New Entrants
    • 5.2.4. Threat to Substitute Products and Services
    • 5.2.5. Competitive Rivalry Within the Industry

6. Market Drivers, Restraints, Opportunities, and Challenges Analysis

  • 6.1. Market Drivers
    • 6.1.1. Favorable Government Funding for Vaccine Development
    • 6.1.2. Increasing Investments by Companies
    • 6.1.3. Rising Prevalence of Disease
  • 6.2. Market Restraints
    • 6.2.1. High Cost of Vaccines
    • 6.2.2. Stringent Regulatory Guidelines
  • 6.3. Market Ppportunities
  • 6.4. Market Challenges

7. Market Segmentation

  • 7.1. By Type
    • 7.1.1. Auto Immune Disease Vaccines
    • 7.1.2. Neurological Disease Vaccines
      • 7.1.2.1. ACC-001
      • 7.1.2.2. CAD 106
      • 7.1.2.3. Parkinson's Vaccine
      • 7.1.2.4. Alzheimer's Vaccine
    • 7.1.3. Cancer Vaccines
      • 7.1.3.1. Multikine
      • 7.1.3.2. PR1 Peptide
      • 7.1.3.3. Trovax
      • 7.1.3.4. CYT004-MelQbG10
    • 7.1.4. Infectious Disease Vaccines
      • 7.1.4.1. Hepatitis C Vaccines
      • 7.1.4.2. HIV/AIDS Vaccine
      • 7.1.4.3. Other Infectious Disease Vaccines
  • 7.2. By Geography
    • 7.2.1. North America
      • 7.2.1.1. USA
      • 7.2.1.2. Canada
      • 7.2.1.3. Mexico
    • 7.2.2. Europe
      • 7.2.2.1. Germany
      • 7.2.2.2. France
      • 7.2.2.3. UK
      • 7.2.2.4. Italy
      • 7.2.2.5. Spain
      • 7.2.2.6. Scandinavia
      • 7.2.2.7. BENELUX
      • 7.2.2.8. Rest of Europe
    • 7.2.3. Asia-Pacific
      • 7.2.3.1. Japan
      • 7.2.3.2. China
      • 7.2.3.3. India
      • 7.2.3.4. South Korea
      • 7.2.3.5. Australia & New Zealand
      • 7.2.3.6. Rest of Asia-Pacific
    • 7.2.4. Middle East & Africa
      • 7.2.4.1. GCC
      • 7.2.4.2. South Africa
      • 7.2.4.3. Rest of Middle East & Africa
    • 7.2.5. South America
      • 7.2.5.1. Brazil
      • 7.2.5.2. Argentina
      • 7.2.5.3. Rest of South America

8. Competitive Landscape

  • 8.1. Mergers and Acquisitions Analysis
  • 8.2. Collaborationa and Partnerships
  • 8.3. New Product Launches

9. Key Vendor Analysis

  • 9.1. Agenus Inc
  • 9.2. Bavarian Nordic
  • 9.3. Celtic Pharma
  • 9.4. Cytos Biotechnology
  • 9.5. Dendreon Corp
  • 9.6. GlaxoSmithKline
  • 9.7. Pfizer
  • 9.8. Merck Serono
  • 9.9. Novartis
  • 9.10. Transgene

10. Future Outlook of the Market

Back to Top